Objective To evaluate whether heart rate (HR) was associated with intravenous immunoglobulin (IVIG) responsiveness or development of coronary artery lesions (CALs) in patients with Kawasaki disease.
K awasaki disease is an acute febrile illness in childhood characterized by bilateral conjunctivitis, redness of the lips and oral mucosa, cervical lymphadenopathy, rash, and change in the extremities. High-dose intravenous immunoglobulin (IVIG) has been established as the first-line treatment for patients with Kawasaki disease in the acute phase for its effectiveness in reducing the inflammation and the occurrence of coronary artery lesions (CALs). [1] [2] [3] However, 10%-20% of patients are refractory to the initial IVIG treatment. [4] [5] [6] These patients tend to have fever for longer periods and are considered to be at high risk of presenting with CALs. [4] [5] [6] Therefore, the prediction of unresponsiveness to the initial IVIG and treatment stratification has emerged as an important issue in this era.
Several studies on clinical prediction rules for IVIG responsiveness have been published; Kobayashi et al developed a prediction rule for responsiveness to the initial IVIG treatment, which was validated and showed high discriminative ability. 7 Egami et al reported a good discrimination of nonresponders among patients with Kawasaki disease treated with IVIG using this model. 8 Other studies described the potential for stratifying patients with Kawasaki disease to provide more aggressive treatments to those who are likely to be resistant to IVIG treatment. 9, 10 The published prediction models are based on patients' age, the clinical day of IVIG treatment, and laboratory findings, such as platelet count, C-reactive protein, or liver enzymes.
Heart rate (HR) is a simple approach to assessing the status of pediatric patients. HR is a principal component of various diagnostic criteria such as systemic inflammatory response syndrome, 11 clinical tools such as triage systems in emergency department, 12, 13 or early warning systems for hospitalized patients. 14, 15 Although HR has been widely shown to be a useful predictor in pediatric care, its utility in patients with Kawasaki disease has not been clarified so far. The principal aim of this study was to elucidate the association between HR and responsiveness to the initial IVIG treatment in Kawasaki disease. We also investigated its association with the development of CALs.
Methods
This study was a retrospective cohort study that used the clinical records of patients with Kawasaki disease who were hospitalized in Kobe City Medical Center General Hospital from April 2006 to March 2016. Patients who were diagnosed with Kawasaki disease in the acute phase and treated with IVIG (2g/kg) were included in this study.
According to the Diagnostic Guidelines for Kawasaki Disease (5th revision), 16 patients are diagnosed with typical Kawasaki disease if they have a fever and at least 4 of the 5 principal features (change in extremities, polymorphous exanthema, conjunctival injection, changes in lips and oral cavity, cervical lymphadenopathy), or if they have a fever and 3 principal features with coronary artery abnormalities detected. In this study, we also included patients with Kawasaki disease who had a fever and 3 principal features without coronary artery abnormalities ("incomplete Kawasaki disease") unless other diseases mimicking Kawasaki disease were verified by laboratory findings because inclusion of incomplete Kawasaki disease was considered clinically relevant. Patients were excluded if the initial IVIG treatment had already started before admission to our hospital, if treatments except for aspirin or other antiplatelet drugs were given together with the initial IVIG treatment, or if data pertaining to vital signs were missing. For recurrent patients with Kawasaki disease, only the data for the first hospitalization were included.
The study protocol was approved by the Ethics Committee of Kyoto University, Graduate School and Faculty of Medicine (R0538) and Kobe City Medical Center General Hospital (no.160604).
Because the number of sampling points for vital signs varied from patient to patient, we used the data before IVIG was started. HRs were extracted from electrocardiogram for monitoring, and axillary temperatures were recorded. Using the formula that Daymont et al reported (the calculation  table was obtained from the author through personal  communication) , 17 Heart rate was adjusted for age and body temperature, and given as a z core (age-and temperatureadjusted HR z score [HRZage/temp]).
The primary outcome of this study was responsiveness to the initial IVIG treatment. Patients were defined as being responsive to the IVIG treatment or "responders" if the temperature dropped and stayed below 38.0°C within 24 hours after IVIG had ended. The secondary outcome was the presence of CALs including transient dilatation of coronary arteries. Coronary arteries were considered abnormal when examinations by 2-dimensional echocardiography showed that internal lumen diameters were ≥3 mm in patients <5 years old, ≥4 mm in patients ≥5 years old, or >+2.5 SD for patients' body surface area.
The following data were collected just before initial IVIG was started: white blood cell count, percentage of neutrophils (% neutrophil), hematocrit, platelet count (PLT), serum concentrations of C-reactive protein (CRP), serum sodium, aspartate aminotransferase (AST), alanine aminotransferase, total bilirubin, and serum albumin.
Statistical Analyses
Patient characteristics were described by numbers and percentages for the categorical variables, and medians and IQRs for the continuous variables. The distribution of variables was compared by the Welch t test or Fisher exact test between patients who showed response to the initial IVIG treatment and those who did not.
According to HRZage/temp, the patients were divided into 5 groups at the quintile points, labeled as group 1 (those with the lowest HRZage/temp) to group 5 (those with the highest HRZage/temp). ORs for the outcomes were calculated using multiple logistic regression models using group 3 as the reference group. We constructed 4 models including different variables from the following candidates: sex, clinical day of the initial IVIG treatment, white blood cell count, % neutrophil, hematocrit, PLT, CRP, sodium, AST, total bilirubin, and albumin. Model 1 contained only HRZage/temp as the explanatory variable (crude model); model 2 further included clinical day of the initial IVIG treatment, % neutrophil, PLT, CRP, sodium, and AST (these variables were all included in the Kobayashi score 7 ); model 3 contained the same variables as model 2 plus total bilirubin (included in another prediction rule 18 ), hematocrit and albumin (these variables might affect intravascular volume status); and model 4 included all the candidate variables above (full model). Because the data for several variables were considerably lacking, we conducted multiple imputations by chained equations for these data.
For sensitivity analyses, we conducted multivariable analyses using the models that included the patients' age as the explanatory variable so that the adjusting method could not remove the dependencies of HR on age. We also performed sensitivity analyses using only the data of typical patients with Kawasaki disease, or the data from those without any missing data.
Wald tests were used to obtain P values. All reported P values were 2-tailed, and P values of less than .05 were considered statistically significant. R (v 3.4.2, R Development Core Team, Vienna, Austria) was used for all analyses. 19 
Results
During the study period, a total of 501 patients with Kawasaki disease were hospitalized. Of the 501 patients, 107 patients were excluded; 48 patients were likely to have other diseases mimicking Kawasaki disease; 21 patients were not in the acute phase; 16 patients repeatedly suffered from Kawasaki disease on 2 occasions or more (only the first hospitalization was included in these patients); in 14 patients, essential data were missing; and in 8 patients, the initial IVIG treatments had already started in other institutions. Of the 394 eligible patients, 322 were given IVIG treatment and included in the analyses (Figure 1) .
Of the 322 patients given the initial IVIG treatment at our institution, 224 patients were defined as responsive to the initial IVIG treatment, and the remaining 98 patients were regarded as nonresponders. ALT, alanine aminotransferase; WBC, white blood cell.
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HRZage/temp among the nonrresponders was -0.10, which was lower than that of the responders (median 0.26, P = .006). There were also statistically significant differences between the responders and nonresponders in the distributions of age, sex, % neutrophil, CRP, serum sodium, AST, and total bilirubin. The proportion of patients who presented with CALs was significantly higher among the nonresponders than the responders (17% and 7%, respectively). The median HRZage/temp among the patients with CALs and those without CALs were 0.63 and 0.11, respectively (P = .16). The characteristics of patients according to the groups by HRZage/temp are described in Table II (available at www.jpeds.com).
As described in Table III (available at www.jpeds.com) and Figure 2 , patients whose HRZage/temp belonged to the lowest group (group 1) were at highest risk of being refractory to the initial IVIG treatment. The OR (with 95% CI) for those unresponsive to IVIG in group1 compared with the reference group (group 3) was 2.10 (1.01-4.37) in the crude model (model 1). The other models also revealed similar trends, though these were not statistically significant.
The results of multivariable analyses for CALs are shown in Table IV (available at www.jpeds.com) and Figure 3 . Unlike the results of IVIG responsiveness, the patients with the highest HRZage/temp (group 5) were at higher risk of presenting with CALs compared with the other groups including group 1, which was considered to be at high risk of being refractory to the initial IVIG treatment as previously mentioned. When using the crude model (model 1), the OR (95% CI) for those presenting with CALs among group 5 compared with group 3 was 2.61 (0.86-7.92). The HR corresponding to the quintile points of HRZage/temp are shown in Table V (available at www.jpeds.com).
When plotting HRZage/temp against body temperature, HRZage/temp had no apparent association with body temperature. However, the plot of HRZage/temp and age suggested that there still remained an inverse relationship, which indicated that patients' age appeared to be an important covariate (Figure 4 ; available at www.jpeds.com). Even after adding the patients' age to the models, the patients in group 1 remained at the highest risk of being refractory to the initial IVIG treatment, and those in group 5 were still most likely to develop CALs (Tables VI and VII; available at www.jpeds.com).
We performed a sensitivity analysis using only the data from patients with typical Kawasaki disease, or only the data without missing values, which indicated similar results (Tables VIII-XI; available at www.jpeds.com).
Discussion
The patients with the lowest HRZage/temp (group 1) were at the highest risk of being refractory to the initial IVIG treatment (OR 2.1 [95% CI 1.0-4.4], group 3 as the reference group). This tendency remained even after adjusting for the factors known as predictors for IVIG responsiveness, or factors possibly associated with intravascular volume status.
Although there are no plausible explanations why relative bradycardia was associated with increased risk of being unresponsive to IVIG, the interaction between systemic inflammatory response and activity of the autonomic nerve system might be involved. 20 HR is decreased by vagus nerve activity, and it is increased by activation of the sympathetic nervous system. A large number of studies using data from animals and humans show that vagal activity regulates inflammation and prevents tissue damage from an excessive inflammatory response. 21 We speculated that vagus nerve activity might be increased in group 1, which could counterbalance as the antiinflammatory response. With respect to the occurrence of CALs, Suzuki et al reported that marked tachycardia was a potential risk indicator for CALs in Kawasaki disease. 22 In the study, the mean HR during the fever period was significantly higher among the patients who presented with CALs after adjusting for potential confounders such as age, duration of febrile period, hematocrit, and CRP. A similar observation was described in our study. The relationship between HRs and the development of CALs differed from the relationship between HRs and responsiveness to the initial IVIG treatment. Instead of group 1, the patients with the highest HRs (group 5) were at increased risk of developing CALs.
There are several possible explanations for the dissociation between IVIG responsiveness and occurrence of CALs in terms of association with patient HRs. First, among the patients who were defined as IVIG nonresponders, clinical course might have not been homogeneous. Some patients had persistent fever, then required additional treatments; others only had transient fever and no extra treatment were given. On the other hand, some patients who were defined as responsive to the initial IVIG treatment could have had ongoing Kawasaki disease symptoms. In our study, 66% (19 of 29) of IVIG nonresponders were given the second IVIG treatment in group 1; whereas in group 5, over 90% (17 of 18) of IVIG nonresponders needed the additional IVIG treatment (Table II) , though the interpretation of this result might be difficult because indication for treatment was determined on the basis of various factors. More precise definition of IVIG responsiveness, based on more detailed clinical observation (eg, the extent of fever, timing of recurrence, or other Kawasaki disease symptoms), may reinforce the value of HR in patients with Kawasaki disease.
Second, the development of CALs depends not only on the patient condition but also on the treatments given after the initial IVIG, or possibly on the timing of the initial IVIG administration. Obviously, HR before the initial IVIG treatment cannot be affected directly by the treatments after the initial IVIG, there might exist confounders linking between the pre-IVIG HR and the post-IVIG status, which our decision for the additional treatments would be based on (eg, general appearance or other Kawasaki disease symptoms). The patients, who were considered at high risk of being IVIG nonresponders, or moreover developing CALs, may have been more likely to receive more aggressive treatment after the initial IVIG administration. Furthermore, the initial IVIG treatment itself might have been given at an earlier time. However, the proportion of those who received second IVIG or steroid treatment among groups 1 and 5 were almost the same (29% and 26%, respectively), and this was higher than the other groups (13%-17%). The timing of the initial IVIG administration was not recorded as being earlier in group 1. Therefore, the course of treatments could not sufficiently explain this result.
Third, the difference in inflammatory characteristics among patients might lead to this observation. Wang et al investigated whether Th1/Th2 cytokine profiles in children with Kawasaki disease were involved in IVIG resistance and development of CALs. 23 In this study, the pre-IVIG level of interleukin-6 was higher in patients with Kawasaki disease with CALs than those without CALs, while it was lower in IVIG nonresponders compared with IVIG responders. Diverse inflammatory cytokine profiles among patients with Kawasaki disease would lead to various clinical courses. Some patients might have persistent high fever without developing CALs, others could have aggressive vasculitis even without high fever. However, information of patient's HR and body temperature would not be sufficient to differentiate them. 
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In Table II , we found some differences in patients' characteristics between groups. The patients with the lowest HRZage/temp (group 1) had higher percentage of neutrophil counts; whereas those with the highest HRZage/temp (group 5) appeared to have higher platelet counts. One possible explanation is that the former might be patients who had greater systemic inflammation; the latter might be those with more aggressive vasculitis, which could be associated with diverse profiles of cytokines among patients. Further studies are needed to investigate the clinical utility of HRZage/temp in patients with Kawasaki disease in consideration of other clinical presentations, or laboratory findings including cytokine profiles.
Exploratory plots of HRZage/temp against age or body temperature suggested that there remained some association between HR and age even after adjustment using the formula reported by Daymont et al (Figure 4) . Therefore, we also investigated the model including age as a covariate, but the result did not change. Other sensitivity analyses that showed the same trends strengthened the result.
There were several limitations to our study. First, there were several differences in the method between Daymont's study and our current study. We used axillary temperature, although core temperature was used in Daymont's study. The ethnicity of participants was also different. Second, because this was an observational study, there may have been unknown or unmeasured confounding variables. Patients' anxiety, discomfort, or pain may have increased HR. Use of antipyretics might have affected HR not only through decreasing body temperature but also reducing pain or discomfort. The body temperature might fluctuate depending on patient's sleep-awake cycle or environmental temperature. This study also included a relatively small sample size. We only had 6.5 events per variable in the full model, which might not have yielded sufficient power to detect differences should they exist. There are also no scientifically plausible explanations for the relationship between the lower HR and the higher risk of IVIG responsiveness, or the conflicting result with respect to the development of CALs. Further studies are necessary to explore the association between autonomic nervous activity and clinical course of patients with Kawasaki disease with a theoretical basis for cytokines profiles. ■ 
